CURRENT AND PAST (LAST 5 YEARS) GRANT SUPPORT
From-To Title of project Sources
2001-2005 Mapping Personality Genes Israel Science Foundation PI
2004-2005 Fine mapping of chromosome 8p for a QTL related to anxiety-related traits and pre-pulse inhibition: Defining an endophenotype for schizophrenia NARSAD Distinguished PI
2004-2007 A psychosocial and molecular genetic study of former smokers using a family-based candidate gene and linkage design Phillip Morris PI
2005-2009 Children's emotional regulation: Association with maternal anxiety, maternal behavior, temperament, family stress, and genes Israel Science Foundation (Marsha Kaitz PI, Richard P. Ebstein CI)
2002-2007 International Multi-center ADHD Genetics Project NIH (S. Faraone PI). I am the Israeli coordinator (3 Israeli centers participating)
2005-2007 Genetic predisposition to metabolic syndrome and type II diabetes in schizophrenic patients NARSAD; Independent Kremer PI; I am CI
2006-2008 Identification of Novel Proteins Associated with Autism: Structural Studies on Neuroligins, their Homologs and their AUTISM SPEAKS Partners PIs: J. L. Sussman - collaborating investigators: I. Silman, R. P. Ebstein (Scheinfeld Center & Dept of Psychology, Hebrew University), N. Yirmiya (Dept of Psychology, Hebrew University)
2007-2009 The neurobiological basis of human cooperation, trust and altruistic behaviors: Nexus of molecular genetics, economics, game theory and neural imaging BINCA (Hebrew University internal grant)
2007-2010 Molecular genetic, imaging and psychological studies of human sexuality Israel Science Foundation 'Bikura'
2008-2012 Intergenerational Transmission of Trauma from Terror: A Developmental Perspective National Institute of Health (Prof. S. Faraone is PI, Dr. Marsha Kaitz is Israel PI and I am CI)
2008-2012 Interplay of genes and environment in modulating fetal and infant stress response to prenatal maternal smoking Israel Science Foundation (I am the PI)
2009-2012 Effect of oxytocin receptor inhibitor (Atosiban) during the perinatal period and prevalence of autism spectrum disorders Autism Speaks (I am the PI)

Particular mention should be made of the prestigious BINCA award which we received and was presented by the Hebrew University Center for Converging Sciences and Technologies. The award of our grant was Tuesday, January 30, 2007 from 14:00-17:00 at The Allan Bronfman Family Reception Centre Mount Scopus Campus in the presence of the Bronfman family and the President of the Hebrew University as well as representative of Israeli's Hi-Tec community.

The phrase Converging Sciences and Technologies refers to the synergistic combination of five major fields of science and technology, which are rapidly evolving: Bio: Biophysics, Systems Biology, Biomedicine, & Biotechnology; Info: Information and Computing Sciences and Technology; Nano: Nanoscience and Nanotechnology; Cogno: Cognitive Sciences, Brain Organization and Functions; and Arts and Humanities, Social Science, and Law. The new Center for Converging Sciences & Technologies aims to bridge the gaps that exist between different research fields, enabling better communication and openness throughout the disciplines and leading toward effective collaborations in education and research. A major goal of the Center is to identify and promote the pursuit of scientific questions and the study of scientific challenges and methods, whose solutions and development can only be made by combining the expertise of scientists in diverse fields. The result of these actions is the mutual benefit and advancement of all involved disciplines.

RP EBSTEIN PUBLICATIONS PUBMED (209 peer reviewed)
1. Asherson P, Zhou K, Anney RJ, Franke B, Buitelaar J, Ebstein R et al. A high-density SNP linkage scan with 142 combined subtype ADHD sib pairs identifies linkage regions on chromosomes 9 and 16. Molecular psychiatry 2008 May;13(5):514-521.
2. Brookes KJ, Neale B, Xu X, Thapar A, Gill M, Langley K et al. Differential dopamine receptor D4 allele association with ADHD dependent of proband season of birth. Am J Med Genet B Neuropsychiatr Genet 2008 Jan 5;147(1):94-99.
3. Chen W, Zhou K, Sham P, Franke B, Kuntsi J, Campbell D et al. DSM-IV combined type ADHD shows familial association with sibling trait scores: A sampling strategy for QTL linkage. Am J Med Genet B Neuropsychiatr Genet 2008 Jan 11.
4. Christiansen H, Chen W, Oades RD, Asherson P, Taylor EA, Lasky-Su J et al. Co-transmission of conduct problems with attention-deficit/hyperactivity disorder: familial evidence for a distinct disorder. J Neural Transm 2008;115(2):163-175.
5. Knafo A, Israel S, Darvasi A, Bachner-Melman R, Uzefovsky F, Cohen L et al. Individual differences in allocation of funds in the dictator game associated with length of the arginine vasopressin 1a receptor RS3 promoter region and correlation between RS3 length and hippocampal mRNA. Genes, brain, and behavior 2008 Apr;7(3):266-275.
6. Manor I, Laiba E, Eisenberg J, Meidad S, Lerer E, Israel S et al. Association between trypotphan hydroxylase 2, performance on a continuance performance test and response to methylphenidate in ADHD participants. Am J Med Genet B Neuropsychiatr Genet 2008 Jan 22.
7. Neale BM, Sham PC, Purcell S, Banaschewski T, Buitelaar J, Franke B et al. Population differences in the International Multi-Centre ADHD Gene Project. Genetic epidemiology 2008 Feb;32(2):98-107.
8. Sonuga-Barke EJ, Brookes KJ, Buitelaar J, Anney R, Bitsakou P, Baeyens D et al. Intelligence in DSM-IV combined type attention-deficit/hyperactivity disorder is not predicted by either dopamine receptor/transporter genes or other previously identified risk alleles for attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2008 Apr 5;147(3):316-319.
9. Alfimova MV, Golimbet VE, Gritsenko IK, Lezheiko TV, Abramova LI, Strel'tsova MA et al. Interaction of dopamine system genes and cognitive functions in patients with schizophrenia and their relatives and in healthy subjects from the general population. Neuroscience and behavioral physiology 2007 Sep;37(7):643-650.
10. Amar S, Shamir A, Ovadia O, Blanaru M, Reshef A, Kremer I et al. Mitochondrial DNA HV lineage increases the susceptibility to schizophrenia among Israeli Arabs. Schizophrenia research 2007 Aug;94(1-3):354-358.
11. Anney RJ, Hawi Z, Sheehan K, Mulligan A, Pinto C, Brookes KJ et al. Parent of origin effects in attention/deficit hyperactivity disorder (ADHD): Analysis of data from the international multicenter ADHD genetics (IMAGE) program. Am J Med Genet B Neuropsychiatr Genet 2007 Dec 28.
12. Asherson P, Brookes K, Franke B, Chen W, Gill M, Ebstein RP et al. Confirmation that a specific haplotype of the dopamine transporter gene is associated with combined-type ADHD. The American journal of psychiatry 2007 Apr;164(4):674-677. 13. Bachner-Melman R, Lerer E, Zohar AH, Kremer I, Elizur Y, Nemanov L et al. Anorexia nervosa, perfectionism, and dopamine D4 receptor (DRD4). Am J Med Genet B Neuropsychiatr Genet 2007 Sep 5;144(6):748-756.
14. Bachner-Melman R, Zohar AH, Ebstein RP, Bachar E. The relationship between selflessness levels and the severity of anorexia nervosa symptomatology. Eur Eat Disord Rev 2007 May;15(3):213-220.
15. Golimbet VE, Alfimova MV, Gritsenko IK, Ebstein RP. Relationship between dopamine system genes and extraversion and novelty seeking. Neuroscience and behavioral physiology 2007 Jul;37(6):601-606.
16. Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC. High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophrenia research 2007 Mar;91(1-3):14-21.
17. Lasky-Su J, Banaschewski T, Buitelaar J, Franke B, Brookes K, Sonuga-Barke E et al. Partial replication of a DRD4 association in ADHD individuals using a statistically derived quantitative trait for ADHD in a family-based association test. Biological psychiatry 2007 Nov 1;62(9):985-990.
18. Lerer E, Levi S, Salomon S, Darvasi A, Yirmiya N, Ebstein RP. Association between the oxytocin receptor (OXTR) gene and autism: relationship to Vineland Adaptive Behavior Scales and cognition. Molecular psychiatry 2007 Sep 25.
19. Alfimova MV, Golimbet VE, Gritsenko IK, Lezheiko TV, Abramova LI, Strel'tsova MA et al. [Dopamine system genes interaction and neurocognitive traits in patients with schizophrenia, their relatives and healthy controls from general population]. Zhurnal nevrologii i psikhiatrii imeni SS 2006;106(7):57-63.
20. Amann-Zalcenstein D, Avidan N, Kanyas K, Ebstein RP, Kohn Y, Hamdan A et al. AHI1, a pivotal neurodevelopmental gene, and C6orf217 are associated with susceptibility to schizophrenia. Eur J Hum Genet 2006 Oct;14(10):1111-1119.
21. Bachner-Melman R, Zohar AH, Ebstein RP. An examination of cognitive versus behavioral components of recovery from anorexia nervosa. The Journal of nervous and mental disease 2006 Sep;194(9):697-703.
22. Bachner-Melman R, Zohar AH, Ebstein RP, Elizur Y, Constantini N. How anorexic-like are the symptom and personality profiles of aesthetic athletes? Medicine and science in sports and exercise 2006 Apr;38(4):628-636.
23. Ben Zion IZ, Tessler R, Cohen L, Lerer E, Raz Y, Bachner-Melman R et al. Polymorphisms in the dopamine D4 receptor gene (DRD4) contribute to individual differences in human sexual behavior: desire, arousal and sexual function. Molecular psychiatry 2006 Aug;11(8):782-786.
24. Brookes K, Xu X, Chen W, Zhou K, Neale B, Lowe N et al. The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes. Molecular psychiatry 2006 Oct;11(10):934-953.
25. Ebstein RP. The molecular genetic architecture of human personality: beyond self-report questionnaires. Molecular psychiatry 2006 May;11(5):427-445.
26. Golimbet V, Gritsenko I, Alfimova M, Lebedeva I, Lezheiko T, Abramova L et al. Association study of COMT gene Val158Met polymorphism with auditory P300 and performance on neurocognitive tests in patients with schizophrenia and their relatives. World J Biol Psychiatry 2006;7(4):238-245.
27. Ivo R, Schulze TG, Schumacher J, Kesper K, Muller DJ, Kremer I et al. No evidence for association between NOTCH4 and schizophrenia in a large family-based and case-control association analysis. Psychiatric genetics 2006 Oct;16(5):197-203.
28. Korobochka R, Gritsenko I, Gonen R, Ebstein RP, Ohel G. Association between a functional dopamine D4 receptor promoter region polymorphism (-C521T) and pre-eclampsia: a family-based study. Molecular human reproduction 2006 Feb;12(2):85-88.
29. Korostishevsky M, Kremer I, Kaganovich M, Cholostoy A, Murad I, Muhaheed M et al. Transmission disequilibrium and haplotype analyses of the G72/G30 locus: suggestive linkage to schizophrenia in Palestinian Arabs living in the North of Israel. Am J Med Genet B Neuropsychiatr Genet 2006 Jan 5;141(1):91-95.
30. Lerer E, Kanyas K, Karni O, Ebstein RP, Lerer B. Why do young women smoke? II. Role of traumatic life experience, psychological characteristics and serotonergic genes. Molecular psychiatry 2006 Aug;11(8):771-781.
31. Yirmiya N, Rosenberg C, Levi S, Salomon S, Shulman C, Nemanov L et al. Association between the arginine vasopressin 1a receptor (AVPR1a) gene and autism in a family-based study: mediation by socialization skills. Molecular psychiatry 2006 May;11(5):488-494.
32. Bachner-Melman R, Dina C, Zohar AH, Constantini N, Lerer E, Hoch S et al. AVPR1a and SLC6A4 gene polymorphisms are associated with creative dance performance. PLoS genetics 2005 Sep;1(3):e42.
33. Bachner-Melman R, Gritsenko I, Nemanov L, Zohar AH, Dina C, Ebstein RP. Dopaminergic polymorphisms associated with self-report measures of human altruism: a fresh phenotype for the dopamine D4 receptor. Molecular psychiatry 2005 Apr;10(4):333-335.
34. Bachner-Melman R, Zohar AH, Nemanov L, Heresco-Levy U, Gritsenko I, Ebstein RP. Association between the insulin-like growth factor 2 gene (IGF2) and scores on the Eating Attitudes Test in nonclinical subjects: a family-based study. The American journal of psychiatry 2005 Dec;162(12):2256-2262.
35. Benmoyal-Segal L, Vander T, Shifman S, Bryk B, Ebstein RP, Marcus EL et al. Acetylcholinesterase/paraoxonase interactions increase the risk of insecticide-induced Parkinson's disease. Faseb J 2005 Mar;19(3):452-454.
36. Dina C, Nemanov L, Gritsenko I, Rosolio N, Osher Y, Heresco-Levy U et al. Fine mapping of a region on chromosome 8p gives evidence for a QTL contributing to individual differences in an anxiety-related personality trait: TPQ harm avoidance. Am J Med Genet B Neuropsychiatr Genet 2005 Jan 5;132(1):104-108.
37. Golimbet VE, Gritsenko IK, Alfimova MV, Ebstein RP. [Polymorphic markers of the dopamine D4 receptor gene promoter region and personality traits in mentally healthy individuals from the Russian population]. Genetika 2005 Jul;41(7):966-972.
38. Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biological psychiatry 2005 Mar 15;57(6):577-585.
39. Kremer I, Bachner-Melman R, Reshef A, Broude L, Nemanov L, Gritsenko I et al. Association of the serotonin transporter gene with smoking behavior. The American journal of psychiatry 2005 May;162(5):924-930.
40. Stessman J, Maaravi Y, Hammerman-Rozenberg R, Cohen A, Nemanov L, Gritsenko I et al. Candidate genes associated with ageing and life expectancy in the Jerusalem longitudinal study. Mechanisms of ageing and development 2005 Feb;126(2):333-339.
41. Bachner-Melman R, Zohar AH, Elizur Y, Nemanov L, Gritsenko I, Konis D et al. Association between a vasopressin receptor AVPR1A promoter region microsatellite and eating behavior measured by a self-report questionnaire (Eating Attitudes Test) in a family-based study of a nonclinical population. The International journal of eating disorders 2004 Dec;36(4):451-460.
42. Bah J, Quach H, Ebstein RP, Segman RH, Melke J, Jamain S et al. Maternal transmission disequilibrium of the glutamate receptor GRIK2 in schizophrenia. Neuroreport 2004 Aug 26;15(12):1987-1991.
43. Buskila D, Cohen H, Neumann L, Ebstein RP. An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits. Molecular psychiatry 2004 Aug;9(8):730-731.
44. Lichtenberg P, Bachner-Melman R, Ebstein RP, Crawford HJ. Hypnotic susceptibility: multidimensional relationships with Cloninger's Tridimensional Personality Questionnaire, COMT polymorphisms, absorption, and attentional characteristics. The International journal of clinical and experimental hypnosis 2004 Jan;52(1):47-72.
45. Lowe N, Kirley A, Hawi Z, Sham P, Wickham H, Kratochvil CJ et al. Joint analysis of the DRD5 marker concludes association with attention-deficit/hyperactivity disorder confined to the predominantly inattentive and combined subtypes. American journal of human genetics 2004 Feb;74(2):348-356.
46. Manor I, Corbex M, Eisenberg J, Gritsenkso I, Bachner-Melman R, Tyano S et al. Association of the dopamine D5 receptor with attention deficit hyperactivity disorder (ADHD) and scores on a continuous performance test (TOVA). Am J Med Genet B Neuropsychiatr Genet 2004 May 15;127(1):73-77.
47. Sjoholt G, Ebstein RP, Lie RT, Berle JO, Mallet J, Deleuze JF et al. Examination of IMPA1 and IMPA2 genes in manic-depressive patients: association between IMPA2 promoter polymorphisms and bipolar disorder. Molecular psychiatry 2004 Jun;9(6):621-629.
48. Arbelle S, Benjamin J, Golin M, Kremer I, Belmaker RH, Ebstein RP. Relation of shyness in grade school children to the genotype for the long form of the serotonin transporter promoter region polymorphism. The American journal of psychiatry 2003 Apr;160(4):671-676.
49. Kremer I, Pinto M, Murad I, Muhaheed M, Bannoura I, Muller DJ et al. Family-based and case-control study of catechol-O-methyltransferase in schizophrenia among Palestinian Arabs. Am J Med Genet B Neuropsychiatr Genet 2003 May 15;119(1):35-39.
50. Zohar AH, Dina C, Rosolio N, Osher Y, Gritsenko I, Bachner-Melman R et al. Tridimensional personality questionnaire trait of harm avoidance (anxiety proneness) is linked to a locus on chromosome 8p21. Am J Med Genet B Neuropsychiatr Genet 2003 Feb;117(1):66-69.
51. Alsobrook JP, 2nd, Zohar AH, Leboyer M, Chabane N, Ebstein RP, Pauls DL. Association between the COMT locus and obsessive-compulsive disorder in females but not males. American journal of medical genetics 2002 Jan 8;114(1):116-120.
52. Bachner-Melman R, Ebstein R. No link between hypnotizability and the Self-Monitoring Scale. The American journal of clinical hypnosis 2002 Jul;45(1):21-30.
53. Belmaker RH, Shapiro J, Vainer E, Nemanov L, Ebstein RP, Agam G. Reduced inositol content in lymphocyte-derived cell lines from bipolar patients. Bipolar disorders 2002 Feb;4(1):67-69.
54. Benjamin J, Ebstein RP, Belmaker RH. Personality genetics, 2002. The Israel journal of psychiatry and related sciences 2002;39(4):271-279.
55. Cohen H, Buskila D, Neumann L, Ebstein RP. Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5- HTTLPR) polymorphism, and relationship to anxiety-related personality traits. Arthritis and rheumatism 2002 Mar;46(3):845-847.
56. Ebstein RP, Zohar AH, Benjamin J, Belmaker RH. An update on molecular genetic studies of human personality traits. Applied bioinformatics 2002;1(2):57-68.
57. Kluger AN, Siegfried Z, Ebstein RP. A meta-analysis of the association between DRD4 polymorphism and novelty seeking. Molecular psychiatry 2002;7(7):712-717.
58. Manor I, Tyano S, Eisenberg J, Bachner-Melman R, Kotler M, Ebstein RP. The short DRD4 repeats confer risk to attention deficit hyperactivity disorder in a family-based design and impair performance on a continuous performance test (TOVA). Molecular psychiatry 2002;7(7):790-794.
59. Manor I, Tyano S, Mel E, Eisenberg J, Bachner-Melman R, Kotler M et al. Family-based and association studies of monoamine oxidase A and attention deficit hyperactivity disorder (ADHD): preferential transmission of the long promoter-region repeat and its association with impaired performance on a continuous performance test (TOVA). Molecular psychiatry 2002;7(6):626-632.
60. Yirmiya N, Pilowsky T, Tidhar S, Nemanov L, Altmark L, Ebstein RP. Family-based and population study of a functional promoter-region monoamine oxidase A polymorphism in autism: possible association with IQ. American journal of medical genetics 2002 Apr 8;114(3):284-287. 61. Auerbach JG, Benjamin J, Faroy M, Geller V, Ebstein R. DRD4 related to infant attention and information processing: a developmental link to ADHD? Psychiatric genetics 2001 Mar;11(1):31-35.
62. Auerbach JG, Faroy M, Ebstein R, Kahana M, Levine J. The association of the dopamine D4 receptor gene (DRD4) and the serotonin transporter promoter gene (5-HTTLPR) with temperament in 12-month-old infants. Journal of child psychology and psychiatry, and allied disciplines 2001 Sep;42(6):777-783.
63. Benjamin J, Ebstein RP, Belmaker RH. Genes for human personality traits: "endophenotypes" of psychiatric disorders? World J Biol Psychiatry 2001 Apr;2(2):54-57.
64. Dobrusin M, Corbex M, Kremer I, Murad I, Muhaheed M, Bannoura I et al. No evidence for linkage by transmission disequilibrium test analysis of microsatellite marker D22S278 and schizophrenia in a Palestinian Arab and in a German population. American journal of medical genetics 2001 May 8;105(4):328-331.
65. Manor I, Eisenberg J, Tyano S, Sever Y, Cohen H, Ebstein RP et al. Family-based association study of the serotonin transporter promoter region polymorphism (5-HTTLPR) in attention deficit hyperactivity disorder. American journal of medical genetics 2001 Jan 8;105(1):91-95.
66. Murad I, Kremer I, Dobrusin M, Muhaheed M, Bannoura I, Muller DJ et al. A family-based study of the Cys23Ser 5HT2C serotonin receptor polymorphism in schizophrenia. American journal of medical genetics 2001 Apr 8;105(3):236-238.
67. Shaltiel G, Shamir A, Nemanov L, Yaroslavsky Y, Nemets B, Ebstein RP et al. Inositol monophosphatase activity in brain and lymphocyte-derived cell lines of bipolar patients. World J Biol Psychiatry 2001 Apr;2(2):95-98.
68. Shamir A, Sjoholt G, Ebstein RP, Agam G, Steen VM. Characterization of two genes, Impa1 and Impa2 encoding mouse myo-inositol monophosphatases. Gene 2001 Jun 27;271(2):285-291.
69. Yirmiya N, Pilowsky T, Nemanov L, Arbelle S, Feinsilver T, Fried I et al. Evidence for an association with the serotonin transporter promoter region polymorphism and autism. American journal of medical genetics 2001 May 8;105(4):381-386.
70. Benjamin J, Osher Y, Kotler M, Gritsenko I, Nemanov L, Belmaker RH et al. Association between tridimensional personality questionnaire (TPQ) traits and three functional polymorphisms: dopamine receptor D4 (DRD4), serotonin transporter promoter region (5-HTTLPR) and catechol O-methyltransferase (COMT). Molecular psychiatry 2000 Jan;5(1):96-100.
71. Benjamin J, Osher Y, Lichtenberg P, Bachner-Melman R, Gritsenko I, Kotler M et al. An interaction between the catechol O-methyltransferase and serotonin transporter promoter region polymorphisms contributes to tridimensional personality questionnaire persistence scores in normal subjects. Neuropsychobiology 2000;41(1):48-53.
72. Ebstein RP, Benjamin J, Belmaker RH. Personality and polymorphisms of genes involved in aminergic neurotransmission. European journal of pharmacology 2000 Dec 27;410(2-3):205-214.
73. Eisenberg J, Zohar A, Mei-Tal G, Steinberg A, Tartakovsky E, Gritsenko I et al. A haplotype relative risk study of the dopamine D4 receptor (DRD4) exon III repeat polymorphism and attention deficit hyperactivity disorder (ADHD). American journal of medical genetics 2000 Jun 12;96(3):258-261.
74. Horowitz R, Kotler M, Shufman E, Aharoni S, Kremer I, Cohen H et al. Confirmation of an excess of the high enzyme activity COMT val allele in heroin addicts in a family-based haplotype relative risk study. American journal of medical genetics 2000 Oct 9;96(5):599-603.
75. Kotler M, Manor I, Sever Y, Eisenberg J, Cohen H, Ebstein RP et al. Failure to replicate an excess of the long dopamine D4 exon III repeat polymorphism in ADHD in a family-based study. American journal of medical genetics 2000 Jun 12;96(3):278-281.
76. Kremer I, Rietschel M, Dobrusin M, Mujaheed M, Murad I, Blanaru M et al. No association between the dopamine D3 receptor Bal I polymorphism and schizophrenia in a family-based study of a Palestinian Arab population. American journal of medical genetics 2000 Dec 4;96(6):778-780.
77. Lichtenberg P, Bachner-Melman R, Gritsenko I, Ebstein RP. Exploratory association study between catechol-O-methyltransferase (COMT) high/low enzyme activity polymorphism and hypnotizability. American journal of medical genetics 2000 Dec 4;96(6):771-774.
78. Manor I, Ebstein R. [Hereditary basis of attention deficit and hyperactivity disorder]. Harefuah 2000 Nov;139(9-10):382-385.
79. Manor I, Kotler M, Sever Y, Eisenberg J, Cohen H, Ebstein RP et al. Failure to replicate an association between the catechol-O-methyltransferase polymorphism and attention deficit hyperactivity disorder in a second, independently recruited Israeli cohort. American journal of medical genetics 2000 Dec 4;96(6):858-860.
80. Marcus EL, Sokoloff M, Nemanov L, Ebstein RP. Determination of serum albumin in older adults. A need for specification of the assay method. Journal of the American Medical Directors Association 2000 Nov-Dec;1(6):261-266.
81. Mujaheed M, Corbex M, Lichtenberg P, Levinson DF, Deleuze JF, Mallet J et al. Evidence for linkage by transmission disequilibrium test analysis of a chromosome 22 microsatellite marker D22S278 and bipolar disorder in a Palestinian Arab population. American journal of medical genetics 2000 Dec 4;96(6):836-838.
82. Shapira M, Tur-Kaspa I, Bosgraaf L, Livni N, Grant AD, Grisaru D et al. A transcription-activating polymorphism in the ACHE promoter associated with acute sensitivity to anti-acetylcholinesterases. Human molecular genetics 2000 May 22;9(9):1273-1281.
83. Auerbach J, Geller V, Lezer S, Shinwell E, Belmaker RH, Levine J et al. Dopamine D4 receptor (D4DR) and serotonin transporter promoter (5-HTTLPR) polymorphisms in the determination of temperament in 2-month-old infants. Molecular psychiatry 1999 Jul;4(4):369-373.
84. Eisenberg J, Mei-Tal G, Steinberg A, Tartakovsky E, Zohar A, Gritsenko I et al. Haplotype relative risk study of catechol-O-methyltransferase (COMT) and attention deficit hyperactivity disorder (ADHD): association of the high-enzyme activity Val allele with ADHD impulsive-hyperactive phenotype. American journal of medical genetics 1999 Oct 15;88(5):497-502.
85. Kotler M, Barak P, Cohen H, Averbuch IE, Grinshpoon A, Gritsenko I et al. Homicidal behavior in schizophrenia associated with a genetic polymorphism determining low catechol O-methyltransferase (COMT) activity. American journal of medical genetics 1999 Dec 15;88(6):628-633.
86. Kotler M, Cohen H, Kremer I, Mel H, Horowitz R, Ohel N et al. No association between the serotonin transporter promoter region (5-HTTLPR) and the dopamine D3 receptor (BalI D3DR) polymorphisms and heroin addiction. Molecular psychiatry 1999 Jul;4(4):313-314.
87. Nemanov L, Ebstein RP, Belmaker RH, Osher Y, Agam G. Effect of bipolar disorder on lymphocyte inositol monophosphatase mRNA levels. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 1999 Mar;2(1):25-29.
88. Benjamin J, Ebstein RP, Lesch KP. Genes for personality traits: implications for psychopathology. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 1998 Dec;1(2):153-168.
89. Ebstein RP, Levine J, Geller V, Auerbach J, Gritsenko I, Belmaker RH. Dopamine D4 receptor and serotonin transporter promoter in the determination of neonatal temperament. Molecular psychiatry 1998 May;3(3):238-246.
90. Shamir A, Ebstein RP, Nemanov L, Zohar A, Belmaker RH, Agam G. Inositol monophosphatase in immortalized lymphoblastoid cell lines indicates susceptibility to bipolar disorder and response to lithium therapy. Molecular psychiatry 1998 Nov;3(6):481-482.
91. Benjamin J, Ebstein RP, Belmaker RH. Personality genetics. The Israel journal of psychiatry and related sciences 1997;34(4):270-280.
92. Ebstein RP, Belmaker RH. Saga of an adventure gene: novelty seeking, substance abuse and the dopamine D4 receptor (D4DR) exon III repeat polymorphism. Molecular psychiatry 1997 Sep;2(5):381-384.
93. Ebstein RP, Gritsenko I, Nemanov L, Frisch A, Osher Y, Belmaker RH. No association between the serotonin transporter gene regulatory region polymorphism and the Tridimensional Personality Questionnaire (TPQ) temperament of harm avoidance. Molecular psychiatry 1997 May;2(3):224-226.
94. Ebstein RP, Macciardi F, Heresco-Levi U, Serretti A, Blaine D, Verga M et al. Evidence for an association between the dopamine D3 receptor gene DRD3 and schizophrenia. Human heredity 1997 Jan-Feb;47(1):6-16.
95. Ebstein RP, Nemanov L, Klotz I, Gritsenko I, Belmaker RH. Additional evidence for an association between the dopamine D4 receptor (D4DR) exon III repeat polymorphism and the human personality trait of Novelty Seeking. Molecular psychiatry 1997 Oct-Nov;2(6):472-477.
96. Ebstein RP, Segman R, Benjamin J, Osher Y, Nemanov L, Belmaker RH. 5-HT2C (HTR2C) serotonin receptor gene polymorphism associated with the human personality trait of reward dependence: interaction with dopamine D4 receptor (D4DR) and dopamine D3 receptor (D3DR) polymorphisms. American journal of medical genetics 1997 Feb 21;74(1):65-72.
97. Kohn Y, Ebstein RP, Heresco-Levy U, Shapira B, Nemanov L, Gritsenko I et al. Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects. Eur Neuropsychopharmacol 1997 Feb;7(1):39-43.
98. Kotler M, Cohen H, Segman R, Gritsenko I, Nemanov L, Lerer B et al. Excess dopamine D4 receptor (D4DR) exon III seven repeat allele in opioid-dependent subjects. Molecular psychiatry 1997 May;2(3):251-254.
99. Segman RH, Ebstein RP, Heresco-Levy U, Gorfine M, Avnon M, Gur E et al. Schizophrenia, chronic hospitalization and the 5-HT2C receptor gene. Psychiatric genetics 1997 Summer;7(2):75-78.
100. Shoham S, Ebstein RP. The distribution of beta-amyloid precursor protein in rat cortex after systemic kainate-induced seizures. Experimental neurology 1997 Oct;147(2):361-376.
101. Wildenauer DB, Hallmayer J, Schwab SG, Albus M, Eckstein GN, Zill P et al. Searching for susceptibility genes in schizophrenia by genetic linkage analysis. Cold Spring Harbor symposia on quantitative biology 1996;61:845-850.
102. Maier W, Minges J, Eckstein N, Brodski C, Albus M, Lerer B et al. Genetic relationship between dopamine transporter gene and schizophrenia: linkage and association. Schizophrenia research 1996 May;20(1-2):175-180.
103. Hammerman-Rozenberg R, Cohen A, Ginsberg G, Maaravi Y, Ebstein RP, Stessman J. Laboratory reference values for the 70 year olds. Israel journal of medical sciences 1996 Aug;32(8):611-620.
104. Ebstein RP, Novick O, Umansky R, Priel B, Osher Y, Blaine D et al. Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of Novelty Seeking. Nature genetics 1996 Jan;12(1):78-80.
105. Ebstein RP, Nemanov L, Lubarski G, Dano M, Trevis T, Korczyn AD. Changes in expression of lymphocyte amyloid precursor protein mRNA isoforms in normal aging and Alzheimer's disease. Brain research 1996 Jan;35(1-2):260-268.
106. Schwab SG, Albus M, Hallmayer J, Honig S, Borrmann M, Lichtermann D et al. Evaluation of a susceptibility gene for schizophrenia on chromosome 6p by multipoint affected sib-pair linkage analysis. Nature genetics 1995 Nov;11(3):325-327.
107. Mulcrone J, Whatley SA, Marchbanks R, Wildenauer D, Altmark D, Daoud H et al. Genetic linkage analysis of schizophrenia using chromosome 11q13-24 markers in Israeli pedigrees. American journal of medical genetics 1995 Apr 24;60(2):103-108.
108. Wertheimer E, Litvin Y, Ebstein RP, Bennet ER, Barbetti F, Accili D et al. Deletion of exon 3 of the insulin receptor gene in a kindred with a familial form of insulin resistance. The Journal of clinical endocrinology and metabolism 1994 May;78(5):1153-1158.
109. Ebstein RP, Bennett ER, Shoham S, Sokoloff M. Lithium regulation of G protein mRNA levels in PC12 and GH3 cells: theoretical implications for gene therapy in bipolar illness. Gene therapy 1994;1 Suppl 1:S86.
110. Kuritzky A, Bennet E, Hering R, Ebstein R. Reduced sensitivity of lymphocyte beta-adrenergic receptors in migraine. Headache 1993 Apr;33(4):198-200.
111. Ebstein RP, Bennett ER, Sokoloff M, Shoham S. The effect of nerve growth factor on cholinergic cells in primary fetal striatal cultures: characterization by in situ hybridization. Brain research 1993 Jun 8;73(2):165-172.
112. Shoham S, Wertman E, Ebstein RP. Iron accumulation in the rat basal ganglia after excitatory amino acid injections--dissociation from neuronal loss. Experimental neurology 1992 Nov;118(2):227-241.
113. Bennett ER, Yedgar S, Lerer B, Ebstein RP. Phospholipase A2 activity in Epstein-Barr virus-transformed lymphoblast cells from schizophrenic patients. Biological psychiatry 1991 Jun 1;29(11):1058-1062.
114. Shoham S, Newman ME, Wertman E, Ebstein RP. Cortical second messengers after NBM damage: no change in responses to cholinergic agonists. Pharmacology, biochemistry, and behavior 1990 Jul;36(3):507-513.
115. Lerer B, Bleich A, Bennett ER, Ebstein RP, Balkin J. Platelet adenylate cyclase and phospholipase C activity in posttraumatic stress disorder. Biological psychiatry 1990 Apr 1;27(7):735-740.
116. Ebstein RP, Bennett ER, Hadjez J, Silver H, Yedgar S, Lerer B. Cyclic AMP second messenger signal generation in EBV-transformed lymphoblastoid cells from schizophrenic patients. Journal of psychiatric research 1990;24(2):121-127.
117. Itzchaky S, Lerer B, Ebstein RP. Uptake of 3H-spiperone by lymphocytes in schizophrenia. Journal of psychiatric research 1989;23(3-4):221-227.
118. Ebstein RP, Lerer B, Shapira B, Shemesh Z, Moscovich DG, Kindler S. Cyclic AMP second-messenger signal amplification in depression. Br J Psychiatry 1988 May;152:665-669.
119. Ebstein RP, Lerer B, Bennett ER, Shapira B, Kindler S, Shemesh Z et al. Lithium modulation of second messenger signal amplification in man: inhibition of phosphatidylinositol-specific phospholipase C and adenylate cyclase activity. Psychiatry research 1988 Apr;24(1):45-52.
120. Lerer B, Ebstein RP, Shestatsky M, Shemesh Z, Greenberg D. Cyclic AMP signal transduction in posttraumatic stress disorder. The American journal of psychiatry 1987 Oct;144(10):1324-1327.
121. Ebstein RP, Moscovich D, Zeevi S, Amiri Z, Lerer B. Effect of lithium in vitro and after chronic treatment on human platelet adenylate cyclase activity: postreceptor modification of second messenger signal amplification. Psychiatry research 1987 Jul;21(3):221-228.
122. Ebstein RP, Bennett ER, Stessman J, Lerer B. Isoelectric focusing of human platelet phospholipase C: evidence for multimolecular forms. Life sciences 1987 Jan 12;40(2):161-167.
123. Ebstein RP, Oppenheim G, Zlotogorski Z, van Dijk Y, Doron A, Stessman J. Age related decline in aluminum-activated human platelet adenylate cyclase: post-receptor changes in cyclic AMP second messenger signal amplification in normal aging and dementia of the Alzheimer type. Life sciences 1986 Sep 29;39(13):1167-1175.
124. Ebstein RP, Oppenheim G, Ebstein BS, Amiri Z, Stessman J. The cyclic AMP second messenger system in man: the effects of heredity, hormones, drugs, aluminum, age and disease on signal amplification. Progress in neuro-psychopharmacology & biological psychiatry 1986;10(3-5):323-353.
125. Ebstein RP, Mintzer J, Lipschitz Y, Shemesh Z, Stessman J. Hormone and forskolin-stimulated cyclic AMP accumulation in human lymphocytes: reliability of longitudinal time measurements. Experientia 1986 Jul 15;42(7):838-841.
126. Ebstein RP, Lerer B, Bennett ER, Dayek DB, Newman ME, Shapira B et al. Second messenger function in lymphocytes and platelets: a comparison of peripheral and central mechanisms. Clinical neuropharmacology 1986;9 Suppl 4:350-352.
127. Stessmann J, Mintzer J, Lipschitz Y, Shemesh Z, Goldin LR, Ebstein RP. Heritability of forskolin and hormone-stimulated adenylate cyclase activity in human lymphocytes. Journal of cyclic nucleotide and protein phosphorylation research 1985;10(4):317-326.
128. Ebstein RP, Stessman J, Eliakim R, Menczel J. The effect of age on beta-adrenergic function in man: a review. Israel journal of medical sciences 1985 Mar;21(3):302-311.
129. Ebstein RP, Steinitz M, Mintzer J, Lipshitz I, Stessman J. Beta-adrenergic-stimulated adenylate cyclase activity in normal and EBV-transformed lymphocytes. Experientia 1985 Dec 15;41(12):1552-1554.
130. Stessman J, Eliakim R, Cahan C, Ebstein RP. Deterioration of beta-receptor-adenylate cyclase function in elderly, hospitalized patients. Journal of gerontology 1984 Nov;39(6):667-672.
131. Oppenheim G, Mintzer J, Halperin Y, Eliakim R, Stessman J, Ebstein RP. Acute desensitization of lymphocyte beta-adrenergic-stimulated adenylate cyclase in old age and Alzheimer's disease. Life sciences 1984 Oct 22;35(17):1795-1802.
132. Hamburger-Bar R, Ebstein RP, Belmaker RH. Vasopressin effect on learning in 6-hydroxydopamine-pretreated rats: correlation with caudate vasopressin levels. Biological psychiatry 1984 May;19(5):735-743.
133. Goldberg M, Hattab J, Meir D, Ebstein RP, Belmaker RH. Plasma cyclic AMP and cyclic GMP in childhood-onset psychoses. Journal of autism and developmental disorders 1984 Jun;14(2):159-164.
134. Ebstein RP, Oppenheim G, Stessman J. Alzheimer's disease: isoproterenol and prostaglandin E1-stimulated cyclic AMP accumulation in lymphocytes. Life sciences 1984 Jun 4;34(23):2239-2243.
135. Ebstein RP, Lerer B, Shlaufman M, Belmaker RH. The effect of repeated electroconvulsive shock treatment and chronic lithium feeding on the release of norepinephrine from rat cortical vesicular preparations. Cellular and molecular neurobiology 1983 Sep;3(3):191-201.
136. Zohar J, Spiro D, Novack A, Ebstein RP, Belmaker RH. Lack of benefit from magnesium in lithium toxicity. Neuropsychobiology 1982;8(1):10-11.
137. Zohar J, Lerer B, Ebstein RP, Belmaker RH. Lithium does not prevent agonist-induced subsensitivity of human adenylate cyclase. Biological psychiatry 1982 Mar;17(3):343-350.
138. Lerer B, Jabotinsky-Rubin K, Bannet J, Ebstein RP, Belmaker RH. Electroconvulsive shock prevents dopamine receptor supersensitivity. European journal of pharmacology 1982 May 7;80(1):131-134.
139. Eisenberg J, Brecher-Fride E, Weizman R, Ebstein RP, Belmaker RH. Dopamine receptors in a rat model of minimal brain dysfunction. Neuropsychobiology 1982;8(3):151-155.
140. Ebstein RP, Seamon K, Creveling CR, Daly JW. Release of norepinephrine from brain vesicular preparations: effects of an adenylate cyclase activator, forskolin, and a phosphodiesterase inhibitor. Cellular and molecular neurobiology 1982 Sep;2(3):179-192.
141. Ebstein RP, Daly JW. Release of norepinephrine and dopamine from brain vesicular preparations: effects of adenosine analogues. Cellular and molecular neurobiology 1982 Sep;2(3):193-204.
142. Bannet J, Belmaker RH, Ebstein RP. Individual differences in the response of dopamine receptor number to chronic haloperidol treatment. Biological psychiatry 1981 Nov;16(11):1059-1065.
143. Bannet J, Lerer B, Ebstein RP, Ben-David M, Belmaker RH. Lack of effect of beta-2 adrenergic stimulation on human prolactin. Psychoneuroendocrinology 1981;6(2):177-179.
144. Belmaker RH, Bannet J, Brecher-Fride E, Yanai J, Ebstein RP. The effect of haloperidol feeding on dopamine receptor number in ten mouse strains. Clinical genetics 1981 May;19(5):353-356.
145. Goldman Z, Ebstein RP, Lerer B, Zohar J, Hermoni M, Belmaker RH. Haloperidol blood levels during dosage reduction in chronic schizophrenic patients. Neuropsychobiology 1981;7(6):281-284.
146. Kobrin I, Ebstein R, Belmaker R, Ben-Ishay D. Cyclic AMP generation in medulla oblongata and hypothalamus of hypertension-prone and -resistant rats. Journal of neurochemistry 1981 Mar;36(3):1285-1288.
147. Lerer B, Ebstein RP, Belmaker RH. Subsensitivity of human beta-adrenergic adenylate cyclase after salbutamol treatment of depression. Psychopharmacology 1981;75(2):169-172.
148. Rimon R, Averbuch I, Rozick P, Fijman-Danilovich L, Kara T, Dasberg H et al. Serum and CSF levels of haloperidol by radioimmunoassay and radioreceptor assay during high-dose therapy of resistant schizophrenic patients. Psychopharmacology 1981;73(2):197-199.
149. Bannet J, Belmaker RH, Ebstein RP. The effect of drug holidays in an animal model of tardive dyskinesia. Psychopharmacology 1980;69(2):223-224.
150. Bannet J, Ebstein RP, Belmaker RH. Clinical aspects of the interaction of lithium and stimulants. Br J Psychiatry 1980 Feb;136:204.
151. Bannet J, Gillis S, Ebstein RP, Belmaker RH. Effect of chronic sulpiride on striatal spiperone binding. International pharmacopsychiatry 1980;15(6):334-337.
152. Belmaker RH, Bracha HS, Ebstein RP. Platelet monoamine oxidase in affective illness and alcoholism. Schizophrenia bulletin 1980;6(2):320-323.
153. Belmaker RH, Dasberg H, Ebstein RP. Does neuroleptic blocking of dopamine receptors continue after chronic treatment? Progress in biochemical pharmacology 1980;16:109-118.
154. Belmaker RH, Kon M, Ebstein RP, Dasberg H. Partial inhibition by lithium of the epinephrine-stimulated rise in plasma cyclic GMP in humans. Biological psychiatry 1980 Feb;15(1):3-8.
155. Belmaker RH, Lerner Y, Ebstein RP. Rapid neuroleptization reconsidered. The American journal of psychiatry 1980 Jan;137(1):129-130.
156. Belmaker RH, Zohar J, Ebstein RP. Cyclic nucleotides in mental disorder. Advances in cyclic nucleotide research 1980;12:187-198.
157. Ebstein RP, Eliashar S, Belmaker RH, Ben-Uriah Y, Yehuda S. Chronic lithium treatment and dopamine-mediated behavior. Biological psychiatry 1980 Jun;15(3):459-467.
158. Ebstein RP, Hermoni M, Belmaker RH. The effect of lithium on noradrenaline-induced cyclic AMP accumulation in rat brain: inhibition after chronic treatment and absence of supersensitivity. The Journal of pharmacology and experimental therapeutics 1980 Apr;213(1):161-167.
159. Hermoni M, Lerer B, Ebstein RP, Belmaker RH. Chronic lithium prevets reserpine-induced supersensitivity of adeylate cyclase. The Journal of pharmacy and pharmacology 1980 Jul;32(7):510-511.
160. Kobrin I, Ebstein R, Ben-Ishay D. Cyclic AMP generation in hypothalamus of hypertension-prone and -resistant rats. Clin Sci (Lond) 1980 Dec;59 Suppl 6:247s-249s.
161. Lerer B, Birmacher B, Ebstein RP, Belmaker RH. 48-hour depressive cycling induced by antidepressant. Br J Psychiatry 1980 Aug;137:183-185.
162. Lerer B, Ebstein RP, Felix A, Belmaker RH. Lithium amelioration of reserpine-induced hypoactivity in rats. International pharmacopsychiatry 1980;15(6):338-343.
163. Bannet J, Avni J, Weissenberg E, Ebstein RP, Belmaker RH. Salivary lithium. Br J Psychiatry 1979 Apr;134:446.
164. Belmaker RH, Ebstein RB. [Biological research on psychosis]. Harefuah 1979 Apr 15;96(8):491-493.
165. Belmaker RH, Ebstein RP, Dasberg H, Levy A, Sedvall G, Van Praag HM. The effect of propranolol treatment in shizophrenia on CSF amine metabolites and prolactin. Psychopharmacology 1979 Jun 21;63(3):293-296.
166. Belmaker RH, Lehrer R, Ebstein RP, Lettik H, Kugelmass S. A possible cardiovascular effect of lithium. The American journal of psychiatry 1979 Apr;136(4B):577-579.
167. Bracha H, Ebstein R, Belmaker RH. Possible mechanism of lithium's effect in bronchial asthma. The American journal of psychiatry 1979 May;136(5):734.
168. Ebstein RP, Pickholz D, Belmaker RH. Dopamine receptor changes after long-term haloperidol treatment in rats. The Journal of pharmacy and pharmacology 1979 Aug;31(8):558-559.
169. Ebstein RP, Pickholz D, Sternberg S, Strajelevich D, Belmaker RH. Chronic high dose propranolol does not increase dopamine receptor number. The Journal of pharmacy and pharmacology 1979 Dec;31(12):860-861.
170. Oppenheim G, Ebstein RP, Belmaker RH. Effect of lithium on the physostigmine-induced behavioral syndrome and plasma cyclic GMP. Journal of psychiatric research 1979;15(2):133-138.
171. Belmaker RH, Ebstein RP, Biederman J, Stern R, Berman M, van Praag HM. The effect of L-dopa and propranolol on human CSF cyclic nucleotides. Psychopharmacology 1978 Jul 19;58(3):307-310.
172. Belmaker RH, Hattab J, Ebstein RP. Plasma dopamine-beta-hydroxylase in childhood psychosis. Journal of autism and childhood schizophrenia 1978 Sep;8(3):293-298.
173. Ebstein RP, Reches A, Belmaker RH. Lithium inhibition of the adenosine-induced increase of adenylate cyclase activity. The Journal of pharmacy and pharmacology 1978 Feb;30(2):122-123.
174. Lichtshtein D, Dobkin J, Ebstein RP, Biederman J, Rimon R, Belmaker RH. Gamma-aminobutyric acid (GABA) in the CSF of schizophrenic patients before and after neuroleptic treatment. Br J Psychiatry 1978 Feb;132:145-148.
175. Reches A, Ebstein RP, Belmaker RH. The differential effect of lithium on noradrenaline- and dopamine-sensitive accumulation of cyclic AMP in guinea pig brain. Psychopharmacology 1978 Jul 6;58(2):213-216.
176. Wald D, Ebstein RP, Belmaker RH. Haloperidol and lithium blocking of the mood response to intravenous methylphenidate. Psychopharmacology 1978 Apr 14;57(1):83-87.
177. Zohar J, Biederman J, Rimon R, Ebstein R, Belmaker RH. Clinical correlates of CSF cyclic nucleotides in schizophrenia. The American journal of psychiatry 1978 Feb;135(2):253-255.
178. Belmaker RH, Ebstein R, Benbenisty D. Electrophoretic pattern of plasma MAO in schizophrenia and affective illness. Journal of psychiatric research 1977;13(2):119-123.
179. Belmaker RH, Galon A, Perez L, Ebstein R. Platelet MAO in schizophrenics with and without family history of schizophrenia. Br J Psychiatry 1977 Nov;131:551-552.
180. Belmaker RH, Reches A, Ebstein RP. Platelet monoamine oxidase in schizophrenia. Lancet 1977 Oct 15;2(8042):821.
181. Biederman J, Rimon R, Ebstein R, Belmaker RH, Davidson JT. Cyclic AMP in the CSF of patients with schizophrenia. Br J Psychiatry 1977 Jan;130:64-67.
182. Ebstein RP, Kara T, Belmaker RH. The effect of Li on the glucagon-sensitive adenylate cyclase in vivo in man. Acta pharmacologica et toxicologica 1977 Jul;41(1):80-83.
183. Feine R, Belmaker RH, Rimon R, Ebstein RP. Platelet monoamine oxidase in women with premenstrual syndrome. Neuropsychobiology 1977;3(2-3):105-110.
184. Gershon ES, Belmaker RH, Ebstein R, Jonas WZ. Plasma MAO activity unrelated to genetic vulnerability to primary affective illness. Archives of general psychiatry 1977 Jun;34(6):731-734.
185. Kadouch R, Belmaker RH, Ebstein RP, Peres L. Thphenidate. Neuropsychobiology 1977;3(4):250-255.
186. Reches A, Ebstein RP, Belmaker RH. d-amphetamine inhibition of platelet MAO from schizophrenic patients. Biological psychiatry 1977 Oct;12(5):655-659.
187. Rimon R, Belmaker RH, Ebstein R. Psychosomatic aspects of juvenile rheumatoid arthritis. Scandinavian journal of rheumatology 1977;6(1):1-10.
188. Belmaker RH, Ebbesen K, Ebstein R, Rimon R. Platelet monoamine oxidase in schizophrenia and manic-depressive illness. Br J Psychiatry 1976 Sep;129:227-232.
189. Belmaker RH, Ebstein R, Rimon R, Wyatt RJ, Murphy DL. Electrophoresis of platelet monoamine oxidase in schizophrenia and manic-depressive illness. Acta psychiatrica Scandinavica 1976 Jul;54(1):67-72.
190. Belmaker RH, Ebstein RP, Schoenfeld H, Rimon R. The effect of haloperidol on epinephrine-stimulated adenylate cyclase in humans. Psychopharmacology 1976 Sep 17;49(2):215-217.
191. Biederman J, Rimon R, Ebstein R, Zohar J, Belmaker R. Neuroleptics reduce spinal fluid cyclic AMP in schizophrenic patient. Neuropsychobiology 1976;2(5-6):324-327.
192. Ebstein R, Belmaker R, Grunhaus L, Rimon R. Lithium inhibition of adrenaline-stimulated adenylate cyclase in humans. Nature 1976 Feb 5;259(5542):411-413.
193. Ebstein R, Belmaker RH, Benbenisty D, Rimon R. Electrophoretic pattern of red blood cell catechol-o-methyltransferase in schizophrenia and manic-depressive illness. Biological psychiatry 1976 Oct;11(5):613-623.
194. Ebstein RP, Biederman J, Rimon R, Zohar J, Belmaker RH. Cyclic GMP in the CSF of patients with schizophrenia before and after neuroleptic treatment. Psychopharmacology 1976 Dec 21;51(1):71-74.
195. Grunhaus L, Ebstein R, Belmaker R, Sandler SG, Jonas W. A twin study of human red blood cell catechol-o-methyl transferase. Br J Psychiatry 1976 May;128:494-498.
196. Park DH, Kashimoto T, Ebstein RP, Goldstein M. Purification and immunochemical characterization of dopamine beta-hydroxylase from human pheochromocytoma. Molecular pharmacology 1976 Jan;12(1):73-81.
197. Freedman LS, Ebstein RP, Goldstein M, Axelrod FB, Dancis J. Serum dopamine-beta-hydroxylase in familial dysautonomia. The Journal of laboratory and clinical medicine 1975 Jun;85(6):1008-1012.
198. Coleman M, Campbell M, Freedman LS, Roffman M, Ebstein RP, Goldstein M. Serum dopamine-beta-hydroxylase levels in Down's syndrome. Clinical genetics 1974;5(4):312-315.
199. Ebstein RP, Freedman LS, Lieberman A, Park DH, Pasternack B, Goldstein M et al. A familial study in serum dopamine-beta-hydroxylase levels in torsion dystonia. Neurology 1974 Jul;24(7):684-687.
200. Goldstein M, Freedman LS, Ebstein RP, Park DH. Studies on dopamine-beta-hydroxylase in mental disorders. Journal of psychiatric research 1974;11:205-210.
201. Goldstein M, Freedman LS, Ebstein RP, Park DH, Kashimoto T. Proceedings: Human serum dopamine-beta-hydroxylase: relationship to sympathetic activity in physiological and pathological states. Psychopharmacology bulletin 1974 Jul;10(3):25.
202. Goldstein M, Freedman LS, Ebstein RP, Park DH, Kashimoto T. Human serum dopamine-beta-hydroxylase: relationship to sympathetic activity in physiological and pathological states. Advances in biochemical psychopharmacology 1974;12(0):105-119.
203. Kashimoto T, Park D, Ebstein RP, Goldstein M, Levitz M, Yaverbaum S. A radioimmunoassay for dopamine-beta-hydroxylase using a glass-bound antibody. Experientia 1974 Nov 15;30(11):1363-1364.
204. Ebstein RP, Park DH, Freedman LS, Levitz SM, Ouchi T, Goldstein M. A radioimmunoassay of human circulatory dopamine-beta-hydroxylase. Life sciences 1973 Oct 1;13(7):769-784.
205. Freedman LS, Ebstein RP, Park DH, Levitz SM, Goldstein M, Davis S et al. The effect of cold pressor test in man on serum immunoreactive dopamine-beta-hydroxylase and on dopamine-beta-hydroxylase activity. Research communications in chemical pathology and pharmacology 1973 Nov;6(3):873-878.
206. Ebstein RP, Ebstein BS, Samuel D, Berger BD. Differential sensitivity of amygdala and hypothalamus to amphetamine-induced release of norepinephrine. Journal of neurochemistry 1972 Nov;19(11):2703-2705.
207. Ebstein RP, Gerson U. The non-waxy component of the armored-scale insect sheild. Biochimica et biophysica acta 1971 Jun 22;237(3):550-555.
208. Applebaum SW, Ebstein RP, Wyatt GR. Dissociation of ribonucleic acid from silkmoth pupae by heat and dimethylsulfoxide: evidence for specific cleavage points. Journal of molecular biology 1966 Oct 28;21(1):29-41.
209. Rappaport R, Ebstein RP. Duration of Stimulus and Latent Periods Preceding Furrow Formation in Sand Dollar Eggs. The Journal of experimental zoology 1965 Apr;158:373-382.